Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration (MANT3_ASC)
Primary Purpose
Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc
Status
Unknown status
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3
Sponsored by
About this trial
This is an interventional treatment trial for Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc
Eligibility Criteria
Inclusion Criteria:
- Male and female patients aged 19-70 years
- Among the subjects with low back pain, conventional conservative treatment is performed, but the back pain or hip pain persists for more than 3 months, and it is determined that the cause of the back pain is a degenerative disc (MRI checks for a degenerative disc)
- Has Oswestry Disability score(ODI) ≥ 30%
- Has Visual Analogue Scale(VAS) ≥ 4
- Between lumbar 1-sacral 1, Magnetic Resonance Imaging (MRI) grade according to the Pfirrmann classification is 3~4.
- Has one or two degenerative lumbar discs identified by MRI (Confirmation of low back pain due to disc through various nerve block procedures.)
- Consent was prepared for stem cell administration
Exclusion Criteria:
- Patient requiring surgery due to severe pain in lower extremities due to severe nerve compression due to severe lumbar stenosis or prolapse of lumbar nucleus.
- patient with spinal instability, spondylitis, or vertebral fracture
- type 3 Modic change is in an endplate
- Patient whose disc height has decreased by more than 1/2 due to severe disc degenerative change
- Patient with severe osteoporosis (The average value of the T score in the lumbar spine bone density test is -2.5 or less)
- has undergone surgery, such as disc resection, on the disc to which the cells will be administered
- Patient who received lumbar epidural steroid injection 3 weeks before cell administration
- Pregnant or lactating women
Among female patients who are likely to become pregnant during the clinical trial, who do not use medically acceptable methods of contraception
- medically acceptable methods of contraception: condom, Oral contraception lasting for at least 3 months, Has received an infusion pill before 3 months, using an injectable or implantable contraceptive, or installed an intrauterine contraceptive device
- has a history of psychiatry or who are currently undergoing treatment, who judged that it is difficult to proceed with the clinical trial under the judgment of the researcher
- Patient with drug or alcohol addiction who cannot understand the purpose and method of this clinical trial
- Patient who participated in other clinical trials within 3 months prior to participation in the trial
- Patient who may affect this clinical trial due to serious medical conditions (hypertension not controlled by drugs, diabetes not controlled by drugs, cirrhosis, kidney failure, tumors)
- Patient with a history of malignant tumors within the last 5 years
- has a history of administration of cell therapy products
- Other persons who have clinically significant findings deemed inappropriate for this clinical trial due to medical judgment by the person in charge of the clinical trial
Sites / Locations
- CHA University, CHA Bundang Medical Center
Outcomes
Primary Outcome Measures
1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection
It will be considered safe and tolerated in the absence of the following:
Grade 3 (NCI grading system) or higher adverse reactions related to cell products
Any evidence that the cells are contaminated with infectious substances
Any evidence that cells show tumorigenic potential
Secondary Outcome Measures
Confirmation of the degree of pain improvement in VAS
on a scale of 0 to 10, with 0 meaning no pain and 10 meaning the worst pain you can imagine
Confirmation of the degree of improvement in disability (ODI)
on a scale of 0 to 3, with 0 meaning no disability and 10 meaning severe disability
Confirmation of increase in water content in the nucleus using MRI
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05011474
Brief Title
Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration
Acronym
MANT3_ASC
Official Title
Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 23, 2021 (Actual)
Primary Completion Date
January 20, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Inbo Han
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate the safety and efficacy of autologous adipose-derived mesenchymal stem cell spheroids pretreated with matrillin-3 in chronic low back pain patients with lumbar intervertebral disc degeneration.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
This clinical trial is a Phase 1/2a, open and researcher-led clinical trial. Subjects will be enrolled in succession, signed informed consent, and administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 to each eligible subject meeting all selection criteria.
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3
Intervention Description
Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.
Primary Outcome Measure Information:
Title
1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection
Description
It will be considered safe and tolerated in the absence of the following:
Grade 3 (NCI grading system) or higher adverse reactions related to cell products
Any evidence that the cells are contaminated with infectious substances
Any evidence that cells show tumorigenic potential
Time Frame
During Clinical Trial Period
Secondary Outcome Measure Information:
Title
Confirmation of the degree of pain improvement in VAS
Description
on a scale of 0 to 10, with 0 meaning no pain and 10 meaning the worst pain you can imagine
Time Frame
before and at 1 week, 1, 3, 6 months after stem cell injection
Title
Confirmation of the degree of improvement in disability (ODI)
Description
on a scale of 0 to 3, with 0 meaning no disability and 10 meaning severe disability
Time Frame
before stem cell injection and at 1 week, 1, 3, and 6 months after injection
Title
Confirmation of increase in water content in the nucleus using MRI
Time Frame
before stem cell injection and at 1 and 6 month after injection
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients aged 19-70 years
Among the subjects with low back pain, conventional conservative treatment is performed, but the back pain or hip pain persists for more than 3 months, and it is determined that the cause of the back pain is a degenerative disc (MRI checks for a degenerative disc)
Has Oswestry Disability score(ODI) ≥ 30%
Has Visual Analogue Scale(VAS) ≥ 4
Between lumbar 1-sacral 1, Magnetic Resonance Imaging (MRI) grade according to the Pfirrmann classification is 3~4.
Has one or two degenerative lumbar discs identified by MRI (Confirmation of low back pain due to disc through various nerve block procedures.)
Consent was prepared for stem cell administration
Exclusion Criteria:
Patient requiring surgery due to severe pain in lower extremities due to severe nerve compression due to severe lumbar stenosis or prolapse of lumbar nucleus.
patient with spinal instability, spondylitis, or vertebral fracture
type 3 Modic change is in an endplate
Patient whose disc height has decreased by more than 1/2 due to severe disc degenerative change
Patient with severe osteoporosis (The average value of the T score in the lumbar spine bone density test is -2.5 or less)
has undergone surgery, such as disc resection, on the disc to which the cells will be administered
Patient who received lumbar epidural steroid injection 3 weeks before cell administration
Pregnant or lactating women
Among female patients who are likely to become pregnant during the clinical trial, who do not use medically acceptable methods of contraception
medically acceptable methods of contraception: condom, Oral contraception lasting for at least 3 months, Has received an infusion pill before 3 months, using an injectable or implantable contraceptive, or installed an intrauterine contraceptive device
has a history of psychiatry or who are currently undergoing treatment, who judged that it is difficult to proceed with the clinical trial under the judgment of the researcher
Patient with drug or alcohol addiction who cannot understand the purpose and method of this clinical trial
Patient who participated in other clinical trials within 3 months prior to participation in the trial
Patient who may affect this clinical trial due to serious medical conditions (hypertension not controlled by drugs, diabetes not controlled by drugs, cirrhosis, kidney failure, tumors)
Patient with a history of malignant tumors within the last 5 years
has a history of administration of cell therapy products
Other persons who have clinically significant findings deemed inappropriate for this clinical trial due to medical judgment by the person in charge of the clinical trial
Facility Information:
Facility Name
CHA University, CHA Bundang Medical Center
City
Seongnam-si
State/Province
Gyeonggi-do
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Links:
URL
https://sites.google.com/view/inbolab/home
Description
Related Info
Learn more about this trial
Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration
We'll reach out to this number within 24 hrs